Accessibility Menu
Vistagen Therapeutics logo

Vistagen Therapeutics(OTC) VSTA

Market Cap$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-100%
1 Year-92%
1 Month+6%
$0.26
+1.38%
+0.00Today
After hours$0.26+$0.00 (+0.94%)
Vistagen Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.262026-08-31
Vistagen Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.59%USD 0.242026-08-24
1 month+5.81%USD 0.242026-07-31
3 month-56.03%USD 0.582026-06-02
Year to date-61.47%USD 0.662025-12-31
1 year-92.37%USD 3.342025-08-29
3 year-95.69%USD 5.922023-09-01
5 year-99.72%USD 91.802021-09-01
Since inception-99.98%USD 1,470.002011-06-21

Vistagen Therapeutics Financials at a Glance

Market Cap

$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

R$1.74B

Net Income (TTM)

R$488.28M

EPS (TTM)

-$1.70

P/E Ratio

-0.15

Dividend

$0.00

Beta (Volatility)

2.10 (High)

Price

$0.26

Volume

467,375.574

Open

$0.26

Previous Close

$0.26

Daily Range

$0.24 - $0.26

52-Week Range

$0.20 - $5.14

Estimated Earnings Date

Nov 6, 2025

VSTA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vistagen Therapeutics

Vasta Platform Limited is a Brazilian education firm that provides K-12 private schools with a variety of educational resources, both digital and print. The company operates through two main divisions: the Content & EdTech Platform and the Digital Platform, serving a broad network of partner schools and students.

Products and Services
  • Offers essential and supplementary learning materials, including textbooks and structured programs
  • Manages online and physical retail channels for educational products
  • Provides university entrance exam preparation courses
Growth Outlook
  • Network expanded to 4,508 partner schools, educating approximately 1.335 million students
  • Revenue growth observed with Q3 2025 revenue at BRL 249.6 million
  • Strong gross profit margin of 67.9% in Q3 2025 indicates operational efficiency
Financial Highlights
  • Q3 2025 net income reported at -BRL 87.2 million, reflecting ongoing investment in growth
  • Trailing twelve months (TTM) gross profit margin stands at 63.6%, showcasing profitability potential
  • Current ratio of 1.5 indicates solid short-term financial health
Vasta Platform Limited is positioned in the growing education sector, focusing on K-12 private schools in Brazil. The company's dual-platform approach allows it to cater to diverse educational needs, enhancing its market presence. Recent financial data indicates a commitment to growth, despite current net losses, with a focus on expanding its partner network and improving operational efficiencies. The strong gross profit margin suggests that Vasta is well-equipped to navigate the competitive landscape of educational resources.
AI Generated • Aug 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

41

CEO

Shawn K. Singh

Website

www.vistagen.com

Headquarters

São Paulo, SP 01310-100, BR

VSTA Financials

Key Financial Metrics (TTM)

Gross Margin

63.64%

Operating Margin

1.75%

Net Income Margin

-11.48%

Return on Equity

-2.42%

Return on Capital

5.93%

Return on Assets

-1.72%

Earnings Yield

-6.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

44.38M

Volume

467.38K

Avg. Volume

4.00M

Financials (TTM)

Gross Profit

R$1.06B

Operating Income

R$352.94M

EBITDA

R$844.89M

Operating Cash Flow

R$292.16M

Capital Expenditure

-R$93.23M

Free Cash Flow

R$198.93M

Cash & ST Invst.

R$390.87M

Total Debt

R$1.20B

Vistagen Therapeutics Performance Analysis

Vistagen Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31BRL -227,300N/A
20242024-03-31BRL 1,064,000N/A
20252025-03-31BRL 486,000-54.3%
20262026-03-31BRL 1,269,000161.1%
Vistagen Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31217.4%
Q12025-03-31-38.4%
Q22025-06-30-16.7%
Q32025-09-30-30.4%
Vistagen Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31BRL -8.5115.4%
20242024-03-31BRL -1.52-82.2%
20252025-03-31BRL -1.679.8%
20262026-03-31BRL -1.839.9%
Vistagen Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-311047.8%
Q12025-03-31-100.5%
Q22025-06-30-1619.9%
Q32025-09-30-5.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

R$249.60M

+13.4%

Gross Profit

R$169.52M

+21.9%

Gross Margin

67.92%

N/A

Market Cap

$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.21K

N/A

Employees

1,808

N/A

Net Income

-R$59.77M

+22.5%

EBITDA

R$52.26M

+38.1%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

R$390.87M

+10.1%

Total Debt

R$1.20B

+4.1%

Accounts Receivable

R$575.25M

+10.0%

Inventory

R$288.04M

-14.0%

Long Term Debt

R$828.47M

+40.4%

Short Term Debt

R$369.91M

-34.0%

Return on Assets

-1.72%

N/A

Return on Invested Capital

0.30%

N/A

Free Cash Flow

R$75.01M

+60.7%

Operating Cash Flow

R$96.31M

+41.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
USNAUSANA Health Sciences, Inc.
$14.26+1.57%
BGSB&G Foods, Inc.
$3.47-1.42%
LNDBrasilAgro - Companhia Brasileira de Propriedades Agrícolas
$3.80-0.52%
LWAYLifeway Foods, Inc.
$26.03-1.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About VSTA

What is the current price of Vistagen Therapeutics?

Vistagen Therapeutics is trading at $0.26 per share.

What is the 52-week range for Vistagen Therapeutics?

Over the past 52 weeks, Vistagen Therapeutics has traded between $0.20 and $5.14.

How much debt does Vistagen Therapeutics have?

As of the most recent reporting period, Vistagen Therapeutics reported total debt of R$783.00K.

How much cash does Vistagen Therapeutics have on hand?

Vistagen Therapeutics reported R$16.99M in cash and cash equivalents in its most recent financial results.

What is Vistagen Therapeutics’s dividend yield?

Vistagen Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services